Idera Pharmaceuticals

Idera Pharmaceuticals

Idera Pharmaceuticals was founded to exploit DNA-based drug discovery platforms, specifically targeting toll-like receptors to modulate immune responses. The company's research roots trace back to early work on antisense oligonucleotides, but its most advanced program became tilsotolimod, a TLR9 agonist that entered Phase 3 trials for metastatic melanoma. The firm operated as a publicly traded entity on NASDAQ, with headquarters in Exton, Pennsylvania, and a secondary presence in Cambridge, Massachusetts. Idera's strategy centered on developing novel immunotherapies through a proprietary pipeline. Its lead asset, tilsotolimod, was tested in the ILLUMINATE-301 trial, a pivotal Phase 3 study evaluating the drug in combination with Bristol Myers Squibb's Yervoy (ipilimumab) for patients with anti-PD-1 refractory advanced melanoma (per clinicaltrials.gov, NCT03315871). The company also had earlier-stage programs in autoimmune and inflammatory diseases. Geographically, Idera's operations were US-based, with clinical activities spanning North America and Europe. By 2022, Idera employed roughly 25–30 professionals, according to public filings. The company had no additional offices beyond its Exton and Cambridge locations. In September 2022, Idera completed a reverse merger with Sio Gene Therapies, effectively delisting from NASDAQ and ceasing operations as an independent entity (per SEC filing, September 2022). This merger ended its 24-year run as a public biotech firm.